Philips announced that the PreciseOnco consortium, led by the company, has been awarded a €14.9 million grant from the European Union’s Innovative Health Initiative (IHI). The grant will fund a five‑year research and innovation program that includes five clinical studies aimed at improving precision cancer care through advanced imaging, robotic assistance, and minimally invasive therapies.
The €14.9 million grant is complemented by €9 million in in‑kind contributions and additional resources from industry partners, creating a total investment of €23.9 million for the PreciseOnco project. Philips will use the funds to develop spectral imaging, AI‑powered image processing, and robotic guidance systems that enable sub‑millimeter precision in interventional oncology procedures.
This funding positions Philips at the forefront of precision oncology, expanding its portfolio in image‑guided therapy and reinforcing its strategy to integrate AI across its product lines. The initiative is expected to accelerate the adoption of advanced imaging and robotic technologies in European cancer centers, potentially expanding Philips’ market share in the growing interventional oncology segment.
Bert van Meurs, Chief Business Leader for Image Guided Therapy, said the partnership “opens new possibilities for minimally invasive cancer treatment. By combining spectral imaging, AI‑powered software and robotic guidance, we’re developing solutions that help physicians treat cancer with greater precision, confidence and speed.” The quote underscores Philips’ focus on patient‑centric innovation and its commitment to translating AI into tangible clinical benefits.
The grant also dovetails with Philips’ broader AI strategy, which includes the HealthSuite platform and the Azurion system for image‑guided therapy. By investing in spectral imaging and robotic guidance, Philips is building a technology stack that can be deployed across its existing product lines, creating cross‑sell opportunities and reinforcing its competitive moat in precision oncology.
The announcement comes just days before Philips’ Capital Markets Day on February 10 2026, when the company will present its 2026 outlook and discuss strategic priorities. Investors will likely view the grant as a positive signal of Philips’ continued investment in high‑growth, AI‑driven segments, even as the company balances short‑term capital allocation with long‑term innovation.
The content on EveryTicker is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.